Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α‐Positive Advanced Ovarian Cancer

Yongsheng Li, Li Yuan, Ge Lou, Hongbing Cai, Yuzhi Li, Fenghu Li, Li Wang, Xingtao Long, Yi Gong, Chaonan Zhu, Li Li, June Xu, Qi Zhou · 2026

Read Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α‐Positive Advanced Ovarian Cancer by Yongsheng Li, Li Yuan, Ge Lou, Hongbing Cai, Yuzhi Li, Fenghu Li, Li Wang, Xingtao Long, Yi Gong, Chaonan Zhu, Li Li, June Xu, Qi Zhou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13239540.txt.

Description

Yongsheng Li and co-authors report a first trial in China of a targeted ovarian cancer drug, in this 2026 paper. The drug aims at a surface protein found on many ovarian tumors and carries a cell-killing payload. Patients in the trial had cancers that no longer answered standard platinum drugs.

Nineteen patients joined the dose-rising and dose-expansion stages. Most side effects were manageable; the most common severe ones were drops in blood cell counts. Blood tests tracked how the drug moved through the body. The paper gives early safety and dosing data to guide larger trials of the drug in Chinese patients.

Catalog record

CREATORYongsheng Li, Li Yuan, Ge Lou, Hongbing Cai, Yuzhi Li, Fenghu Li, Li Wang, Xingtao Long, Yi Gong, Chaonan Zhu, Li Li, June Xu, Qi Zhou
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13239540

Browse the full library · About the Tower of Babel